New Leaf
SelectiveFiled to raiseNew York, NYBiotechnology, Healthcare, PharmaceuticalsLast fund filed 2018
5 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| New Leaf Biopharma Opportunities IIFiled to raise in 2018, with no closing reported yet. | 2018 | $200M | $0 | 0 |
| New Leaf Ventures IVFiled to raise in 2018, with no closing reported yet. | 2018 | $275M | $0 | 0 |
| New Leaf Growth Fund I | February 2016 | $20M | $20M | 1 |
| New Leaf Ventures IIIFiled to raise in 2014, with no closing reported yet. | 2014 | $375M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 5 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Philippe Chambon | Slowing | Biotech & pharma, Consumer apps & internet, Digital health | 5 | 1 |
| Ronald Hunt | Slowing | Biotech & pharma, Medical devices, Fintech | 11 | 1 |
| Isaac MankeNot on the current fund | Quiet | Biotech & pharma | 3 | 0 |
| Jeani Delagardelle | Quiet | Medical devices, Biotech & pharma | 5 | 0 |
| Liam Ratcliffe | Quiet | Biotech & pharma, Medical devices | 8 | 0 |
| Vijay Lathi | Quiet | Digital health, Manufacturing & industrials | 8 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of New Leaf’s own portfolio companies, based on 34 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of New Leaf’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| SV Life Sciences | 3 | CARDIOKINETIX, Direct Flow Medical, Reshape Medical |
| Advent Life Sciences | 2 | Iterum Therapeutics Bermuda, Iterum Therapeutics plc |
| Atlas Venture | 2 | Neuronetics, Unum Therapeutics |
| Longitude 103.8 East | 2 | Aptinyx, CuraSen Therapeutics |
| Longitude Capital | 2 | Aptinyx, CuraSen Therapeutics |
| Longitude Prime | 2 | Aptinyx, CuraSen Therapeutics |
| Partners Innovation | 2 | Abcuro, QPID |
| U.S Venture Partners | 2 | CARDIOKINETIX, Reshape Medical |
| 270 Healthcare Growth | 1 | ARVINAS HOLDING COMPANY |
| Bain Capital Life Sciences | 1 | Aptinyx |
| Capra CLO Founders | 1 | Iterum Therapeutics Bermuda |
| Highland Capital Partners | 1 | Kyruus |
| Icon Ventures | 1 | Awarepoint |
| Lux Capital | 1 | Kyruus |
| Meritech Capital Partners | 1 | Kit Check |
A shared board seat: a company where filings name a New Leaf partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.